Jazz Pharmaceuticals JAZZ

Jazz Pharmaceuticals PLC is an international biopharmaceutical company headquartered in Dublin, Ireland. The firm is primarily engaged in the identification, development, and commercialisation of products that address unmet medical needs, particularly in the areas of sleep, haematology and oncology. The company was founded in 2003.

The firm has several medications on the market, including Xyrem, for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy, Erwinaze, for the treatment of acute lymphoblastic leukaemia (ALL), and Defitelio for the treatment of severe hepatic veno-occlusive disease (VOD). The firm is also responsible for the commercialisation of Prialt, an intrathecally administered infusion for the management of severe chronic pain in patients who are intolerant of other common pain management treatments. The company has a range of products in the pipeline, at various stages of development, aimed at a range of diseases and conditions, from cancers to Autism spectrum disorders.

The company is committed to the active exploration of new options for patients who are living with serious diseases, often with no or highly limited options, including novel compounds, small molecules, and biologics. The firm is listed on the NASDAQ under the stock ticker JAZZ.

Track JAZZ price changes by adding it to your eToro watchlist.